Novo Nordisk’s Haemophilia B Study: Key Update on Nonacog Beta Pegol

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study.

Study Overview: Novo Nordisk is conducting a study titled ‘Adverse Event Data Collection From External Registries on Nonacog Beta Pegol.’ The study aims to gather data on adverse events from patients with haemophilia B treated with nonacog beta pegol, using information from external registries like PedNet and EUHASS. This research is significant as it helps to monitor the safety profile of the drug in real-world settings.

Intervention/Treatment: The intervention being tested is a drug called Nonacog beta pegol, which is used to treat haemophilia B. It is administered according to routine clinical practice and aims to manage bleeding episodes in patients.

Study Design: This is an observational study with a cohort model and a retrospective time perspective. The primary purpose is to collect and analyze adverse event data from existing registries, providing insights into the drug’s safety profile.

Study Timeline: The study was first submitted on September 21, 2018, and is currently enrolling by invitation. The latest update was submitted on May 30, 2025. These dates are crucial as they indicate the study’s progression and ongoing nature.

Market Implications: The update on this study could positively impact Novo Nordisk’s stock performance by reinforcing investor confidence in the safety and efficacy of Nonacog beta pegol. As safety data is crucial for maintaining market approval and competitive edge, this study could enhance Novo Nordisk’s reputation in the haemophilia treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.